GBL
gamma-butyrolactone
Viewing r1 — May 9, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
GBL (gamma-butyrolactone) — G, liquid ecstasy — is a synthetic depressant of the lactone class. It is a prodrug of GHB: the body converts it to GHB within minutes, and GHB produces every effect. GHB activates inhibitory receptors in the brain, broadly suppressing neural activity and producing sedation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
GHB was first synthesized in 1960 by Henri Laborit as a sedative designed to reach the brain.[1] After GHB was scheduled in 2000, users switched to GBL — still widely available as an industrial solvent, with US production estimated at 185,000 metric tons per year.[2] Today GBL is used primarily as a chemsex drug in gay and bisexual communities across Europe and Australia.[3]
Subjective effects include euphoria, disinhibition, empathogenic warmth, sexual arousal, and sedation. The experience rises to full effect in minutes — a steep rush that compresses what alcohol spreads over hours — then tips abruptly into deep unconsciousness with only a small dose increase. Nausea, dizziness, motor impairment, and memory blackouts are common unwanted effects.
GBL produces physical dependence faster than alcohol or benzodiazepines,[4] and a fraction of a milliliter separates a recreational dose from one that stops breathing. Compulsive redosing accelerates dependence within days, and withdrawal carries real risk of seizures and death. The evidence base rests largely on GHB research and clinical toxicology case reports, with significant gaps in long-term effects.[5]
History[edit]
History
Discovery
GBL has been manufactured for decades as an industrial solvent. GHB, its active form, was first synthesized in 1960 by Henri Laborit — designed as a sedative capable of crossing into the brain[1] — and entered European clinical use as an anesthetic by 1964.
Recreational emergence and scheduling
During the 1980s, GHB was marketed as a bodybuilding supplement based on its ability to stimulate growth hormone release.[6] Through the 1990s, both GHB and GBL spread as club drugs and became linked to drug-facilitated sexual assault and fatalities.[7] The US Congress responded in 2000 by scheduling GHB and designating GBL a List I chemical.[7][8]
Contemporary landscape
GBL use increased after GHB's scheduling — its industrial availability made it a ready substitute, with US production estimated at 185,000 metric tons per year.[2] The UK classified GBL as Class B in 2009 following its first confirmed fatality;[9] France banned public sale in 2011.[4] Today GBL remains a primary chemsex drug in MSM communities across Europe and Australia,[3][10] with ongoing reports of fatalities, severe withdrawal, and complications including kidney failure.[11]
"G" refers interchangeably to GBL, GHB, and 1,4-butanediol in chemsex contexts — a conflation that carries real risk, as their dosing profiles and onset times differ significantly. The name "liquid ecstasy" is misleading: GBL's pharmacology has no relationship to MDMA. GBL's industrial ubiquity — sold as wheel cleaner, paint stripper, and nail polish remover — has made it one of the most accessible controlled-substance precursors globally, with vendors historically using "not for human consumption" labels to skirt regulations.
Chemistry[edit]
Chemistry
Structure
GBL (oxolan-2-one) belongs to the lactone family — cyclic esters that form when a molecule closes into a ring. It is a five-membered ring with one oxygen atom and a carbonyl group, chemically stable under neutral conditions and without stereocenters.[12]
| Molecular formula | C₄H₆O₂ |
| Molecular weight | 86.09 g/mol |
Prodrug relationship
GBL has no receptor activity of its own. Blood enzymes convert it to GHB within approximately one minute of ingestion[13][14] — every pharmacological effect is GHB's. 1,4-butanediol reaches GHB by a slower, liver-mediated pathway. GBL's greater lipophilicity compared to GHB's sodium salt accounts for its faster absorption and brain penetration.[15]
Pharmacology[edit]
Pharmacology
Mechanism of action
GBL has no receptor activity of its own. Blood enzymes convert it to GHB within about one minute,[13][14] and every effect is produced by GHB — confirmed by the complete absence of response in mice lacking GABA-B receptors.[16][17] GHB activates the brain's major inhibitory pathway, but only at concentrations far above the brain's own natural GHB levels.[18][19]
GHB also activates a specific inhibitory receptor subtype that benzodiazepines cannot reach but barbiturates can.[20][21] This explains why benzodiazepines alone provide incomplete relief during GBL withdrawal.
Pharmacokinetics
GBL absorbs rapidly and bypasses the liver's first-pass processing, delivering higher peak GHB levels than an equivalent oral GHB dose. Plasma GHB peaks 20–60 minutes after ingestion,[13][14] then clears quickly — half-life is 20–60 minutes, with only 1–5% of the dose appearing unchanged in urine.[13] Detection windows are short: approximately 6 hours in blood and 10 hours in urine[14] — which complicates forensic investigation of drug-facilitated assault.
Neuroscience[edit]
Neuroscience
Where it acts
GBL's effects are GHB's effects. GHB activates inhibitory receptors across the brain, reducing neurons' ability to fire and suppressing neurotransmitter release.[16] At recreational doses, this produces a distinctive high-amplitude slow-wave brain pattern distinct from natural sleep.[17]
GHB's reinforcing properties come from the brain's reward circuit. It releases the brake on dopamine neurons by activating inhibitory cells that normally hold them in check, flooding the reward center with dopamine[22] — the same pathway alcohol engages.
Neuroadaptation and withdrawal
Chronic use drives adaptations across multiple neurotransmitter systems.[21] When use stops, inhibitory activity collapses and excitatory activity surges — producing tremor, tachycardia, hallucinations, and seizures,[20] pharmacologically similar to alcohol withdrawal but harder to treat.
Animal models consistently fail to replicate the physical dependence seen in human chronic users, and whether this reflects metabolic differences or a deeper neurobiological divergence is unknown.[23] The role of naturally occurring GHB in the brain — present at concentrations sufficient to engage the newly identified CaMKII-alpha target[19] but far below the threshold for activating inhibitory receptors — has not been determined. No longitudinal studies have characterized the long-term cognitive or structural brain effects of chronic GBL dependence and recovery.[5]
Subjective Effects[edit]
Subjective Effects
GBL hits fast. From baseline to full effect takes minutes — a steep rush of warmth, sociability, and physical pleasure that compresses what alcohol spreads over hours. At lower doses the edges of anxiety and inhibition soften; a fraction more and consciousness can drop without warning.
Within the depressant class, GBL sits closest to GHB, which produces the same effects with a slower onset and slightly more dosing room. Alcohol shares the disinhibition and sedation but operates on different receptors, lacks GBL's empathogenic warmth, and unfolds over a much longer arc.
Effect Grid
Full cognitive euphoria dominates the experience, with pronounced disinhibition and sociability enhancement. Sexual arousal enhancement and empathogenic warmth — tactile sensitivity, prosocial openness, emotional closeness — reach their peak expression. Music enhancement is frequently reported.
Motor control impairment becomes noticeable as ataxia. Nausea may occur. Memory suppression (anterograde amnesia) is possible even at this range. The compulsive redosing urge typically emerges here, driven by the short duration and desire to sustain euphoria.
Cognitive impairment is moderate. Judgment is meaningfully affected by the combination of disinhibition and analysis suppression. The steep dose-response curve means the upper end of this range borders on strong effects — a difference of 0.5 mL can shift the experience substantially.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory enhancement · Dreaming enhancement · Proprioceptive distortion · Sleep-transition hallucinations · Visual acuity suppression · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Visual acuity suppression · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Dizziness · Bodily heaviness · Breathing alteration · Physical fatigue · Sexual arousal enhancement · Tactile euphoria · Laughter fits · Nausea · Nystagmus (eye wobbles) · Headache · Pain suppression · Spontaneous body sensations · Vomiting · Involuntary body movements · Temperature dysregulation · Sexual arousal suppression · Stimulation · Bodily dissociation
Physical fatigue · Sexual arousal enhancement · Tactile euphoria · Laughter fits · Nausea · Nystagmus (eye wobbles) · Headache · Pain suppression · Spontaneous body sensations · Vomiting · Involuntary body movements · Sexual arousal suppression · Stimulation · Bodily dissociation
Confusion · Focus suppression · Information processing suppression · Memory suppression · Suggestibility enhancement · Thought deceleration · Delusions of sobriety · Cognitive fatigue · Language suppression · Memory fragmentation · Thought disorganization · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Memory suppression · Thought deceleration · Delusions of sobriety · Cognitive fatigue · Language suppression · Memory fragmentation · Thought disorganization · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Emotional suppression · Anxiety · Dysphoria
Trust enhancement · Communication enhancement · Communication suppression · Emotional susceptibility · Derealization · Cognitive disconnection
Derealization · Cognitive disconnection
Timeline
First awareness of effects: a spreading warmth and mild relaxation. Subtle mood shift detectable within minutes of ingestion.
Rapid escalation to full effects. Euphoria builds quickly, disinhibition and sociability emerge. The speed of this transition is characteristic of GBL.
Maximum intensity — euphoria, disinhibition, empathogenic warmth, and sexual arousal enhancement at common doses; sedation dominates at strong doses. Compulsive redosing urge is strongest here.
Rapid decline in effects. Euphoria and disinhibition fade, replaced by drowsiness. Cognitive function begins returning but residual impairment persists.
Residual sedation and mild fatigue. Possible headache. Cognitive function largely restored but subtle impairment may linger.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- GHB · 1,4-butanediol
Toxicity
Acute toxicity
GBL produces dose-dependent sedation and can suppress breathing fatally.[4] The estimated lethal dose for a 70 kg person is roughly 3.75 mL of pure liquid[14] — close to the upper recreational range. safety citation needed No antidote exists; treatment is airway protection and mechanical ventilation.[4]
GBL is considered more acutely dangerous than oral GHB. It absorbs faster, leaving less time to intervene, and differences as small as 0.5 mL can shift the outcome from recreational to dangerous.[24]
Cancer and genetic toxicity
IARC classifies GBL as Group 3 — inadequate evidence for cancer risk in humans, with animal data suggesting it is not carcinogenic.[15] Genetic toxicity testing is predominantly negative across multiple test systems.[15]
Psychological Risks
GBL impairs judgment, lowers inhibition, and erases recent memory — a combination that creates vulnerability to exploitation and risky behavior.[4] It is colorless, nearly odorless, and causes rapid sedation with memory loss, making it a documented drug-facilitated sexual assault agent.[7]
The compulsive redosing urge is a distinct risk. Short duration and rapid onset create a powerful reinforcing cycle — one documented user was redosing every 30 minutes.[11] Withdrawal itself causes significant psychiatric disturbance: hallucinations in 63% of documented episodes, along with confusion, delusions, and paranoia.[25] Long-term psychological effects remain poorly characterized.[5]
Tolerance and Dependence
Tolerance develops within days of regular use.[4][26] Physical dependence develops faster than with alcohol or benzodiazepines,[4] and cross-tolerance exists between GBL, GHB, and 1,4-butanediol.[27] The tolerance reset period is approximately 1–2 weeks. citation needed
GBL withdrawal can be fatal. Medical supervision is essential for cessation after regular use. Do not attempt unsupervised withdrawal.
In a review of 57 withdrawal episodes, the most common features were tremor (67%), hallucinations (63%), rapid heart rate (63%), insomnia (58%), anxiety, agitation, high blood pressure, sweating, confusion, and disorientation; seizures and muscle breakdown each occurred in 7%.[25] Onset is typically 6–24 hours after the last dose,[28][4] and duration ranges from days to three weeks in severe cases.
Benzodiazepines are first-line treatment but provide incomplete relief.[4][20] Barbiturates and pharmaceutical GHB tapering address GBL's specific receptor targets more directly,[20][21] baclofen shows promise as an add-on,[29] and severe presentations warrant intensive care.[11]
Drug Interactions
GBL's interactions share one mechanism: combining it with any other CNS depressant compounds the risk of breathing stopping.[4] Alcohol worsens clinical outcomes even at moderate amounts.[30][31] Opioids — every member of the class — produce lethal synergistic respiratory depression.[4][14] Ketamine and other dissociatives carry the same lethal classification.[4]
Stimulants — MDMA, amphetamine, cocaine, methamphetamine — mask GBL's sedating effects, hiding how intoxicated a person actually is. When the stimulant wears off, sudden collapse can follow.[3] Benzodiazepines, antipsychotics, and sedating antihistamines all compound sedation and respiratory depression. Baclofen at recreational doses poses lethal risk; it is used medically for withdrawal management only under supervision.[29]
Contraindications
Absolute contraindications:
- Concurrent alcohol use — synergistic respiratory depression; lethal combination[30][4]
- Concurrent opioid use (any) — synergistic respiratory depression; lethal combination[4]
- Concurrent ketamine or other dissociative use — synergistic depression[4]
- Concurrent use of any sedating medication — including benzodiazepines, barbiturates, sedating antihistamines, antipsychotics, muscle relaxants, and prescription sleep aids
Relative contraindications:
- Respiratory conditions (asthma, COPD, sleep apnea) — GBL produces dose-dependent respiratory depression; impaired baseline breathing increases vulnerability
- Heart rhythm disorders — GBL/GHB can cause slow heart rate at active doses; underlying conduction problems may worsen this
- History of seizures — withdrawal produces seizures in ~7% of cases[25]
- History of substance dependence — GBL's rapid onset, short duration, and compulsive redosing create high reinforcement; prior dependence elevates risk
- Pregnancy and breastfeeding — no human safety data exist safety citation needed
Harm Reduction[edit]
Harm Reduction
Forms & Identification
GBL circulates as a colorless liquid with a faint solvent-like odor — easily mistaken for water. It is sold industrially as wheel cleaner, paint stripper, and solvent; purity varies, and industrial products may contain manufacturing impurities not intended for human exposure. Standard reagent tests do not reliably identify or quantify it.
The critical practical concern is measurement. GBL is dosed in fractions of a milliliter, and less than 0.5 mL can separate a recreational dose from a dangerous one. Oral syringes marked in 0.1 mL increments are the only appropriate measuring tool — not teaspoons, eyeballed capfuls, or unmarked pipettes.
Guidelines
- Always measure with an oral syringe marked in 0.1 mL increments. Never estimate, pour from the bottle, or use bottle caps.
- Start with a threshold dose and wait at least 90 minutes before considering redosing. Onset varies and full effects may arrive later than expected — "I don't feel it yet" is a dangerous impulse.
- Set a strict redosing limit beforehand. The short duration creates a powerful compulsive redosing urge; each successive dose compounds risk. A timer or trusted companion can enforce the limit.
- Never use alone. GBL can produce sudden unconsciousness. A sober companion who knows what has been taken, when, and how much is the most effective safety measure.
- Eat a light meal 1–2 hours beforehand. Food slows absorption and moderates peak intensity. Never use on a completely empty stomach.
- Avoid all other depressants — alcohol, opioids, benzodiazepines, ketamine, antihistamines, sleep medications. Even small amounts of alcohol dramatically increase risk.
- Keep the container clearly labeled and stored away from drinks. GBL is colorless and water-miscible; accidental ingestion by others is a documented cause of harm.
Aftercare & Integration
Hydration and light nutrition support recovery after GBL use. Most acute effects resolve within two hours, but fatigue, mild confusion, and mood dip can persist for several hours.
Honest self-monitoring for escalating use is the most important aftercare step. The reinforcement cycle can shift from occasional use to around-the-clock dosing within days. Increasing dosing frequency, or anxiety about running out of supply, are early warning signs of developing dependence.
Recovery & Support
GBL dependence requires medical management — unsupervised withdrawal carries serious risk of seizures, psychiatric disturbance, and death. Anyone using GBL daily or near-daily should seek medical advice before stopping.
Treatment options include medically supervised tapering, inpatient detoxification with benzodiazepines or barbiturates, and ongoing support for psychological dependence. Peer support communities familiar with GHB/GBL-specific challenges exist in many countries, particularly within chemsex harm reduction organizations in Europe and Australia.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unconsciousness with inability to be roused by voice or firm shoulder pressure
- Slow, shallow, or irregular breathing (fewer than 10 breaths per minute)
- Blue or grey lips and fingertips
- Vomiting while unconscious or semi-conscious
- Seizure activity
Immediate steps:
- 1. Call emergency services immediately if the person cannot be woken or is breathing abnormally.
- 2. Place the person in the recovery position (on their side, mouth pointing downward) to prevent choking on vomit.
- 3. Stay with them. Monitor breathing continuously.
- 4. Do NOT induce vomiting — GBL is absorbed too rapidly for this to help, and vomiting while unconscious risks fatal aspiration.
- 5. Do NOT give them food or water.
- 6. Do NOT leave an unconscious person "to sleep it off." GBL-induced unconsciousness is not sleep — respiratory arrest can occur.
What to tell the dispatcher: Substance taken (GBL or "G"), amount if known, time of ingestion, current symptoms, and whether any other substances were involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents: None exist. Treatment is entirely supportive — airway protection and ventilation.
Legal Status[edit]
Legal Status
GBL occupies an unusual legal position: it is a high-volume industrial chemical with no international treaty controls, yet it converts directly to a scheduled substance in the body, and most countries that regulate it do so through domestic law alone.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | List I Chemical (Controlled Substances Act) | Designated List I since 2000.[8] If intended for human consumption, prosecutable as a Schedule I analog under the Federal Analogue Act. Mixtures containing 70% or less GBL may be exempt. Specific penalties under the Hillory J. Farias Act for drug-facilitated sexual assault.[7] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled since December 2009 following the first UK GBL fatality.[9] Since June 2022, industrial users no longer require a controlled drugs licence; Class B status for human consumption is maintained.[32] GHB remains Class C. |
| Australia | Schedule 10 (prohibited substance) | Non-polymerized GBL in preparations for domestic and cosmetic use is prohibited. Criminal penalties in all states and territories. |
| Canada | Schedule VI (CDSA) | Import and export prohibited. Indictable offence carries up to 10 years; summary conviction up to 18 months. |
| France | Banned for public sale/transfer | Sale and transfer to the public banned since 2011.[4] |
| Germany | Not listed in narcotics law | Distribution controlled under the Medicines Act if intended for human consumption. Possession not inherently illegal but may be prosecuted on evidence of intent. |
| International | Not scheduled under any UN treaty | Subject to voluntary EU monitoring as a drug precursor. Regulatory approaches vary widely among member states. |
Prodrug considerations
In the United States, the Federal Analogue Act allows prosecution as a Schedule I analog when intent for human consumption can be demonstrated. A 70% concentration exemption has been exploited by vendors marketing GBL as industrial solvent at sub-threshold concentrations. In much of the EU and parts of Asia and South America, GBL remains legally purchasable as an industrial chemical — its complete conversion to a scheduled substance makes it one of the most significant regulatory gaps in global drug policy.
Legal status varies by jurisdiction and changes over time. This information is not legal advice.
references
- [1]
- [2]
- [3] ^abcGiorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E (2017) When Chems Meet Sex: A Rising Phenomenon Called ChemSex — Current Neuropharmacology doi:10.2174/1570159x15666161117151148
- [4]
- [5] ^abcHenderson DL, Ginsberg JP (2008) Withdrawal, recovery, and long-term sequelae of gamma-butyrolactone dependence: a case report — The American Journal on Addictions doi:10.1080/10550490802266193
- [6] ^Van Cauter E, Plat L, Scharf MB, et al. (1997) Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men — Journal of Clinical Investigation doi:10.1172/jci119587